Cargando…

A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals

BACKGROUND: As (225)Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures. The determination of radiochemical purity (RCP) is an essential QC test. A significant obstacle to RCP testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, James M., Amor-Coarasa, Alejandro, Sweeney, Elizabeth, Wilson, Justin J., Causey, Patrick W., Babich, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688611/
https://www.ncbi.nlm.nih.gov/pubmed/34928478
http://dx.doi.org/10.1186/s41181-021-00151-y
_version_ 1784618386342281216
author Kelly, James M.
Amor-Coarasa, Alejandro
Sweeney, Elizabeth
Wilson, Justin J.
Causey, Patrick W.
Babich, John W.
author_facet Kelly, James M.
Amor-Coarasa, Alejandro
Sweeney, Elizabeth
Wilson, Justin J.
Causey, Patrick W.
Babich, John W.
author_sort Kelly, James M.
collection PubMed
description BACKGROUND: As (225)Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures. The determination of radiochemical purity (RCP) is an essential QC test. A significant obstacle to RCP testing is the disruption of the secular equilibrium between actinium-225 and its daughter radionuclides during labeling and QC testing. In order to accelerate translation of actinium-225 targeted alpha therapy, we aimed to determine the earliest time point at which the RCP of an (225)Ac-labeled radiopharmaceutical can be accurately quantified. RESULTS: Six ligands were conjugated to macrocyclic metal chelators and labeled with actinium-225 under conditions designed to generate diverse incorporation yields. RCP was determined by radio thin layer chromatography (radioTLC) followed by exposure of the TLC plate on a phosphor screen either 0.5, 2, 3.5, 5, 6.5, or 26 h after the plate was developed. The dataset was used to create models for predicting the true RCP for any pre-equilibrium measurement taken at an early time point. The 585 TLC measurements span RCP values of 1.8–99.5%. The statistical model created from these data predicted an independent data set with high accuracy. Predictions made at 0.5 h are more uncertain than predictions made at later time points. This is primarily due to the decay of bismuth-213. A measurement of RCP > 90% at 2 h predicts a true RCP > 97% and guarantees that RCP will exceed 90% after secular equilibrium is reached. These findings were independently validated using NaI(Tl) scintillation counting and high resolution gamma spectroscopy on a smaller set of samples with 10% ≤ RCP ≤ 100%. CONCLUSIONS: RCP of (225)Ac-labeled radiopharmaceuticals can be quantified with acceptable accuracy at least 2 h after radioTLC using various methods of quantifying particle emissions. This time point best balances the need to accurately quantify RCP with the need to safely release the batch as quickly as possible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41181-021-00151-y.
format Online
Article
Text
id pubmed-8688611
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86886112022-01-05 A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals Kelly, James M. Amor-Coarasa, Alejandro Sweeney, Elizabeth Wilson, Justin J. Causey, Patrick W. Babich, John W. EJNMMI Radiopharm Chem Research Article BACKGROUND: As (225)Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures. The determination of radiochemical purity (RCP) is an essential QC test. A significant obstacle to RCP testing is the disruption of the secular equilibrium between actinium-225 and its daughter radionuclides during labeling and QC testing. In order to accelerate translation of actinium-225 targeted alpha therapy, we aimed to determine the earliest time point at which the RCP of an (225)Ac-labeled radiopharmaceutical can be accurately quantified. RESULTS: Six ligands were conjugated to macrocyclic metal chelators and labeled with actinium-225 under conditions designed to generate diverse incorporation yields. RCP was determined by radio thin layer chromatography (radioTLC) followed by exposure of the TLC plate on a phosphor screen either 0.5, 2, 3.5, 5, 6.5, or 26 h after the plate was developed. The dataset was used to create models for predicting the true RCP for any pre-equilibrium measurement taken at an early time point. The 585 TLC measurements span RCP values of 1.8–99.5%. The statistical model created from these data predicted an independent data set with high accuracy. Predictions made at 0.5 h are more uncertain than predictions made at later time points. This is primarily due to the decay of bismuth-213. A measurement of RCP > 90% at 2 h predicts a true RCP > 97% and guarantees that RCP will exceed 90% after secular equilibrium is reached. These findings were independently validated using NaI(Tl) scintillation counting and high resolution gamma spectroscopy on a smaller set of samples with 10% ≤ RCP ≤ 100%. CONCLUSIONS: RCP of (225)Ac-labeled radiopharmaceuticals can be quantified with acceptable accuracy at least 2 h after radioTLC using various methods of quantifying particle emissions. This time point best balances the need to accurately quantify RCP with the need to safely release the batch as quickly as possible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41181-021-00151-y. Springer International Publishing 2021-12-20 /pmc/articles/PMC8688611/ /pubmed/34928478 http://dx.doi.org/10.1186/s41181-021-00151-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Kelly, James M.
Amor-Coarasa, Alejandro
Sweeney, Elizabeth
Wilson, Justin J.
Causey, Patrick W.
Babich, John W.
A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title_full A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title_fullStr A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title_full_unstemmed A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title_short A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
title_sort suitable time point for quantifying the radiochemical purity of (225)ac-labeled radiopharmaceuticals
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688611/
https://www.ncbi.nlm.nih.gov/pubmed/34928478
http://dx.doi.org/10.1186/s41181-021-00151-y
work_keys_str_mv AT kellyjamesm asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT amorcoarasaalejandro asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT sweeneyelizabeth asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT wilsonjustinj asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT causeypatrickw asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT babichjohnw asuitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT kellyjamesm suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT amorcoarasaalejandro suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT sweeneyelizabeth suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT wilsonjustinj suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT causeypatrickw suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals
AT babichjohnw suitabletimepointforquantifyingtheradiochemicalpurityof225aclabeledradiopharmaceuticals